• Explore /
  • Poster
  • / Intracranial and systemic efficacy of repotrectinib in advanced <em>ROS1</em> fusion-positive (<em>ROS1</em>+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.

Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.

Abstract Video & Slides Poster

Authors

Jessica Lin

Jessica Jiyeong Lin

Massachusetts General Hospital Cancer Center, Boston, MA

Jessica Jiyeong Lin , Alexander E. Drilon , Byoung Chul Cho , Enriqueta Felip , Adrianus De Langen , Nong Yang , Sang-We Kim , Shun Lu , Steven Chuan-Hao Kao , Vamsidhar Velcheti , Denis Lucien MORO SIBILOT , Benjamin J. Solomon , Rafal Dziadziuszko , Matthew G Krebs , Parneet Kaur Cheema , Christophe Alfons Dooms , Shanna Stopatschinskaja , Denise Trone , Felipe Ades , D. Ross Camidge

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03093116

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9017)

DOI

10.1200/JCO.2023.41.16_suppl.9017

Abstract #

9017

Poster Bd #

5

Abstract Disclosures

Similar Posters

First Author: Robert Charles Doebele

First Author: Wei Li

First Author: Yuangyuan Zhao

First Author: Salvatore Siena